Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL201 in Parkinson's Disease
NCT03710707Phase 1Completed
- Sponsor
- Denali Therapeutics Inc.
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DNL201 in Parkinson's disease (PD) (3 arms), sponsored by Denali Therapeutics Inc. Primary endpoints: Number of Subjects with Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) at Day 42, Number of Subjects with laboratory test abnormalities at Day 42 and 3 more. Started Dec 2018; status: completed.
02
Drugs
DNL201
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03710707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03710707.